PPT-The Long Last Mile: Challenges of Access to Medicines and Comprehensive Case Management

Dr Gonzalo Domingo PATH Diagnosis and detection of malaria Parasite density Microscopy 1880 Increasing sensitivity P vivax RDT LDH P falciparum RDT HRP2 1990s Ultrasensitive PCR. Whe ther large or small all have one thing in common they need a comprehensive and streamlined information manage ment system Thats where we can help read on to learn more Swiss Post Solutions provides businesses of all sizes with a comprehensive Learning objectives. At the end of the workshop you will be able to:. Consider the important principles of pain and pain management. Use validated tools to assist in assessing patients pain . Outline strategies to manage pain with your patients. Global context of drug regulation. Dr Lembit Rägo. Coordinator. Quality Assurance and Safety: Medicines. Essential Medicines and Health Products. World Health Organization. E-mail: . ragol@who.int. –. lessons from HIV. EPIP, 5 September 2017, Bordeaux. . Ellen ‘t Hoen, LLM. University Medical Centre Groningen, Global Health Unit. @. ellenthoen. www.medicineslawandpolicy.org. Brief history. Stops AIDS National Gathering . 1st November 2014. Aliénor Devali. ère. Health. Action International (HAI) Europe. This document arises from HAI Europe’s Operating Grant 2014, which has received funding from the . Gilles . Forte. Coordinator, Policy, Access and Use Team. Essential . Medicines . and . Health Products. . WHO . mandate . within the . International . Drug Control Conventions. 1961 . Single Convention on Narcotic Drugs (Article 3). WHO EMP and NVI Departments. Access to NCD essential medicines . on the global agenda. Access to chronic disease medicines is required for the fulfilment of MDG8. Governments, in collaboration with the private sector, should give greater priority to treating chronic diseases and improving the accessibility of medicines to treat them (MDG Report 2009). sustainably and equitably financed. Summary Discussion…1. What information needed to estimate cost program of medicines benefits. MBM . Ned to estimate the total economic cost of setting up a MBM program. Draft concept for a new World Bank-led multi-stakeholder initiative . August 2014, Andreas . Seiter. What is AIM 2030?. An initiative to maximize access to innovative medicines for priority diseases in low- and middle income countries (LMICs). Dr Cécile . Macé. . WHO EMP , Mr Arne-Petter . Sanne. WHO MND, . Mr . Ajuebor. Onyema WHO MND. NCD Programme Managers Seminar. 4 June 2014. Access to NCD essential medicines . on the global agenda. Case Management. George Jagoe . EVP, Access & Product Management, MMV. . . The access team at MMV is heavily focused on the needs of control today. 4. Achieving patient impact means addressing many hurdles to access. C. Dr . Manica. . Balasegaram. , WIPO Seminar, 2014. Generic competition needed. MSF Access Campaign. HIV. :. early successes not sustained. 1. st. line ARVs: no product patent protection in India until 2005 = rock bottom prices. . IDM Disease Modeling Symposium. 15 April 2019. Justin M. Cohen, PhD, MPH. No cure. Business as usual systems lead to only a small fraction of incident malaria infections being cured. 2. Asymptomatic cases. Basic enquiry answering. September . 2016. Session aims. Increase awareness of the Medicines Information (MI) services. UK. Wales. Increase awareness of the questions to ask an enquirer. Have practical experience using some resources which will be...